Recent Advances in Molecular Mechanisms of Cancer Immunotherapy

Cancer is among the current leading causes of death worldwide, despite the novel advances that have been made toward its treatment, it is still considered a major public health concern. Considering both the serious impact of cancer on public health and the significant side effects and complications of conventional therapeutic options, the current strategies towards targeted cancer therapy must be enhanced to avoid undesired toxicity. Cancer immunotherapy has become preferable among researchers in recent years compared to conventional therapeutic options, such as chemotherapy, surgery, and radiotherapy. The understanding of how to control immune checkpoints, develop therapeutic cancer vaccines, genetically modify immune cells as well as enhance the activation of antitumor immune response led to the development of novel cancer treatments. In this review, we address recent advances in cancer immunotherapy molecular mechanisms. Different immunotherapeutic approaches are critically discussed, focusing on the challenges, potential risks, and prospects involving their use.

[1]  C. Burton,et al.  Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells. , 2023, Molecular therapy oncolytics.

[2]  R. Drozda,et al.  PD-1/PD-L1 and DNA Damage Response in Cancer , 2023, Cells.

[3]  S. Oka,et al.  Immunological Control of HIV-1 Disease Progression by Rare Protective HLA Allele , 2022, Journal of virology.

[4]  R. Duran,et al.  Tumor response assessment on imaging following immunotherapy , 2022, Frontiers in Oncology.

[5]  S. Swaminathan,et al.  GM-CSF: A Double-Edged Sword in Cancer Immunotherapy , 2022, Frontiers in Immunology.

[6]  P. Pedrazzoli,et al.  Store-Operated Ca2+ Entry Is Up-Regulated in Tumour-Infiltrating Lymphocytes from Metastatic Colorectal Cancer Patients , 2022, Cancers.

[7]  M. Rahim,et al.  Cancer vaccines: past, present and future; a review article , 2022, Discover Oncology.

[8]  S. Chupradit,et al.  Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons , 2022, Cell Communication and Signaling.

[9]  M. D. de Miguel,et al.  New Checkpoint Inhibitors on the Road: Targeting TIM-3 in Solid Tumors , 2022, Current Oncology Reports.

[10]  Yayi He,et al.  Update on lymphocyte-activation gene 3 (LAG-3) in cancers: from biological properties to clinical applications , 2022, Chinese medical journal.

[11]  D. Hanahan Hallmarks of Cancer: New Dimensions. , 2022, Cancer discovery.

[12]  P. Lacal,et al.  Clinical Experience with CTLA-4 Blockade for Cancer Immunotherapy: From the Monospecific Monoclonal Antibody Ipilimumab to Probodies and Bispecific Molecules Targeting The Tumor Microenvironment. , 2021, Pharmacological research.

[13]  Parisa Sharifi,et al.  Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials. , 2021, Clinical immunology.

[14]  Yangqiu Li,et al.  TIM-3 in Leukemia; Immune Response and Beyond , 2021, Frontiers in Oncology.

[15]  Jibiao Wu,et al.  PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy , 2021, Frontiers in Pharmacology.

[16]  S. Windhorst,et al.  Oncogenic activity and cellular functionality of melanoma associated antigen A3. , 2021, Biochemical pharmacology.

[17]  M. Górska,et al.  Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners , 2021, Cancer metastasis reviews.

[18]  L. Fashoyin-Aje,et al.  Systematic Review of PD‐1/PD‐L1 Inhibitors in Oncology: From Personalized Medicine to Public Health , 2021, The oncologist.

[19]  A. Frampton,et al.  Gene of the month: lymphocyte-activation gene 3 (LAG-3) , 2021, Journal of Clinical Pathology.

[20]  J. Eaton,et al.  Cancer Vaccines: Promising Therapeutics or an Unattainable Dream , 2021, Vaccines.

[21]  N. Bhardwaj,et al.  Vaccines for immunoprevention of cancer. , 2021, The Journal of clinical investigation.

[22]  N. G. Olaiya,et al.  Insights into the Role of Biopolymer Aerogel Scaffolds in Tissue Engineering and Regenerative Medicine , 2021, Polymers.

[23]  F. Ciompi,et al.  PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects , 2021, International journal of molecular sciences.

[24]  yang-xin fu,et al.  Next-generation cytokines for cancer immunotherapy , 2021, Antibody therapeutics.

[25]  Rosalie M Sterner,et al.  CAR-T cell therapy: current limitations and potential strategies , 2021, Blood Cancer Journal.

[26]  E. Yahya,et al.  Recent trends in cancer therapy: A review on the current state of gene delivery. , 2021, Life sciences.

[27]  L. Fong,et al.  Conditional Cancer Immunotherapy as a Safer Way to Step on the Gas. , 2021, Cancer discovery.

[28]  M. Adamaki,et al.  Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer , 2021, Cancers.

[29]  Nader Meskin,et al.  Mathematical Models of Cancer and Different Therapies , 2021 .

[30]  W. Cho,et al.  Tumor mutational burden as a tissue-agnostic biomarker for cancer immunotherapy , 2020, Expert review of clinical pharmacology.

[31]  A. Kunnumakkara,et al.  Rationalizing the therapeutic potential of apigenin against cancer. , 2020, Life sciences.

[32]  Chaoliang He,et al.  Biopolymer Immune Implants’ Sequential Activation of Innate and Adaptive Immunity for Colorectal Cancer Postoperative Immunotherapy , 2020, Advanced materials.

[33]  E. Yahya,et al.  A Review on the Medicinal and Aromatic Plants Growing in Libya and Their Therapeutic Properties. , 2020, International Research Journal of Science and Technology.

[34]  M. Lotze,et al.  Intrapleural interleukin-2–expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease , 2020, The Journal of thoracic and cardiovascular surgery.

[35]  C. Solinas,et al.  Targeting CTLA‐4 in cancer: Is it the ideal companion for PD‐1 blockade immunotherapy combinations? , 2020, International journal of cancer.

[36]  H. Nijman,et al.  Tumor-infiltrating lymphocytes in the immunotherapy era , 2020, Cellular & Molecular Immunology.

[37]  A. Haydon,et al.  Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma , 2020, Journal for ImmunoTherapy of Cancer.

[38]  S. Fu,et al.  Wilms' Tumor 1 (WT1): The Vaccine for Cancer. , 2020, Journal of immunotherapy and precision oncology.

[39]  E. Yahya,et al.  THE CYTOTOXICITY EFFECTS OF OUTER MEMBRANE VESICLES ISOLATED FROM HOSPITAL AND LABORATORY STRAINS OF PSEUDOMONAS AERUGINOSA ON HUMAN KERATINOCYTE CELL LINE , 2020 .

[40]  S. M. Toor,et al.  Targeting TIM-3 in solid tumors: innovations in the preclinical and translational realm and therapeutic potential , 2020, Expert opinion on therapeutic targets.

[41]  Qianhong Cen,et al.  A review on development of MUC1-based cancer vaccine. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[42]  Haidong Dong,et al.  Immune resilience in response to cancer therapy , 2020, Cancer Immunology, Immunotherapy.

[43]  C. Kai,et al.  Recombinant SLAMblind Measles Virus Is a Promising Candidate for Nectin-4-Positive Triple Negative Breast Cancer Therapy , 2020, Molecular therapy oncolytics.

[44]  S. Rizal,et al.  A Review on Revolutionary Natural Biopolymer-Based Aerogels for Antibacterial Delivery , 2020, Antibiotics.

[45]  J. Christensen,et al.  Cytotoxic CD8+ T cells in cancer and cancer immunotherapy , 2020, British Journal of Cancer.

[46]  A. Barati,et al.  Current progress in cancer immunotherapy based on natural killer cells , 2020, Cell biology international.

[47]  K. Fisher,et al.  The role of cancer metabolism in defining the success of oncolytic viro-immunotherapy. , 2020, Cytokine & growth factor reviews.

[48]  A. Wali,et al.  Growth Rate and Antibiotic Sensitivity Effect of Some Natural and Petroleum Based Materials on Staphylococcus aureus , 2020 .

[49]  Joe-Marc Chauvin,et al.  TIGIT in cancer immunotherapy , 2020, Journal for ImmunoTherapy of Cancer.

[50]  Elizabeth L Siegler,et al.  Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies , 2020, Frontiers in Immunology.

[51]  N. G. Olaiya,et al.  A Review on Plant Cellulose Nanofibre-Based Aerogels for Biomedical Applications , 2020, Polymers.

[52]  C. Robert A decade of immune-checkpoint inhibitors in cancer therapy , 2020, Nature Communications.

[53]  G. de Pouvourville,et al.  Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective , 2020, Journal for ImmunoTherapy of Cancer.

[54]  Zemin Zhang,et al.  The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications , 2020, Cellular & Molecular Immunology.

[55]  L. Tentori,et al.  Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma. , 2020, Pharmacological research.

[56]  P. Lacal,et al.  Vascular endothelial growth factor receptor 1 in glioblastoma‑associated microglia/macrophages. , 2020, Oncology reports.

[57]  Yanling Liu,et al.  miRNA-5119 regulates immune checkpoints in dendritic cells to enhance breast cancer immunotherapy , 2020, Cancer Immunology, Immunotherapy.

[58]  Thanh Loc Nguyen,et al.  Injectable dual-scale mesoporous silica cancer vaccine enabling efficient delivery of antigen/adjuvant-loaded nanoparticles to dendritic cells recruited in local macroporous scaffold. , 2020, Biomaterials.

[59]  R. Jain,et al.  A framework for advancing our understanding of cancer-associated fibroblasts , 2020, Nature Reviews Cancer.

[60]  K. Hargadon Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints , 2020, Clinical and translational medicine.

[61]  K. Kunimasa,et al.  Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges , 2020, International journal of molecular sciences.

[62]  Kathe P. Fox,et al.  Autoimmune Effects of Lung Cancer Immunotherapy Revealed by Data‐Driven Analysis on a Nationwide Cohort , 2020, Clinical pharmacology and therapeutics.

[63]  I. Witz,et al.  The Tumor Microenvironment , 2012 .

[64]  Camille Guillerey,et al.  TIGIT as an emerging immune checkpoint , 2019, Clinical and experimental immunology.

[65]  J. Sampson,et al.  Brain immunology and immunotherapy in brain tumours , 2019, Nature Reviews Cancer.

[66]  E. Yahya,et al.  Prevalence of Human Papilloma Virus Sub Genotypes following Head and Neck Squamous Cell Carcinomas in Asian Continent, A Systematic Review Article , 2019, Asian Pacific Journal of Cancer Prevention.

[67]  J. Chavez,et al.  Cytokine Release Syndrome: Current Perspectives , 2019, ImmunoTargets and therapy.

[68]  Xiaoshen Zhang,et al.  OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer , 2019, OncoTargets and therapy.

[69]  Michael S. Goldberg,et al.  Improving cancer immunotherapy through nanotechnology , 2019, Nature Reviews Cancer.

[70]  Akintunde Akinleye,et al.  Immune checkpoint inhibitors of PD-L1 as cancer therapeutics , 2019, Journal of Hematology & Oncology.

[71]  I. Melero,et al.  Dendritic cells in cancer immunology and immunotherapy , 2019, Nature Reviews Immunology.

[72]  Christopher M. Jackson,et al.  Mechanisms of immunotherapy resistance: lessons from glioblastoma , 2019, Nature Immunology.

[73]  Q. Pu,et al.  Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy , 2019, mAbs.

[74]  A. Rotte,et al.  Combination of CTLA-4 and PD-1 blockers for treatment of cancer , 2019, Journal of experimental & clinical cancer research : CR.

[75]  D. Kong,et al.  Injectable polypeptide hydrogel-based co-delivery of vaccine and immune checkpoint inhibitors improves tumor immunotherapy , 2019, Theranostics.

[76]  K. Margolin,et al.  Cytokine Therapy. , 2019, Hematology/oncology clinics of North America.

[77]  K. Mossman,et al.  Oncolytic viruses: how “lytic” must they be for therapeutic efficacy? , 2019, Oncoimmunology.

[78]  Brian Ruffell,et al.  Macrophages as regulators of tumour immunity and immunotherapy , 2019, Nature Reviews Immunology.

[79]  A. Umar,et al.  Cancer prevention and screening: the next step in the era of precision medicine , 2019, npj Precision Oncology.

[80]  Rachel S. Riley,et al.  Delivery technologies for cancer immunotherapy , 2019, Nature Reviews Drug Discovery.

[81]  J. Kinet,et al.  Calcium signalling in T cells , 2019, Nature Reviews Immunology.

[82]  T. Waldmann,et al.  Cytokines in the Treatment of Cancer. , 2019, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[83]  Bin Zhou,et al.  Oncolytic cancer therapy with a vaccinia virus strain. , 2018, Oncology reports.

[84]  T. Waldmann Cytokines in Cancer Immunotherapy. , 2018, Cold Spring Harbor perspectives in biology.

[85]  C. Verrill,et al.  An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells. , 2018, Cancer research.

[86]  J. Feijen,et al.  Peptide‐decorated polymeric nanomedicines for precision cancer therapy , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[87]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[88]  J. Dou,et al.  Role of transmembrane glycoprotein mucin 1 (MUC1) in various types of colorectal cancer and therapies: Current research status and updates. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[89]  M. Sadelain,et al.  Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[90]  A. Mantovani,et al.  Cancer Inflammation and Cytokines. , 2018, Cold Spring Harbor perspectives in biology.

[91]  F. Zufall,et al.  A calcium optimum for cytotoxic T lymphocyte and natural killer cell cytotoxicity , 2018, The Journal of physiology.

[92]  D. Pérez-Ibave,et al.  Prostate-specific antigen (PSA) as a possible biomarker in non-prostatic cancer: A review. , 2018, Cancer epidemiology.

[93]  Androulla N. Miliotou,et al.  CAR T-cell Therapy: A New Era in Cancer Immunotherapy. , 2018, Current pharmaceutical biotechnology.

[94]  Christopher M. Jackson,et al.  TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM , 2018, Oncoimmunology.

[95]  T. Shi,et al.  Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints , 2018, International journal of molecular sciences.

[96]  D. Bedognetti,et al.  NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives , 2018, Front. Immunol..

[97]  P. Smolewski,et al.  Immune Checkpoint Inhibitors to Treat Malignant Lymphomas , 2018, Journal of immunology research.

[98]  Chi Zhang,et al.  Genetic abrogation of immune checkpoints in antigen-specific cytotoxic T-lymphocyte as a potential alternative to blockade immunotherapy , 2018, Scientific Reports.

[99]  H. Yamaue,et al.  Cancer Vaccine Therapy Using Carcinoembryonic Antigen - expressing Dendritic Cells generated from Induced Pluripotent Stem Cells , 2018, Scientific Reports.

[100]  Dai Fukumura,et al.  Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges , 2018, Nature Reviews Clinical Oncology.

[101]  R. Salgia,et al.  Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations , 2018, Journal of Immunotherapy for Cancer.

[102]  J. Tavernier,et al.  Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments. , 2018, Cancer research.

[103]  D. Sansom,et al.  CTLA-4: a moving target in immunotherapy. , 2018, Blood.

[104]  Kwangmo Yang,et al.  EpCAM peptide-primed dendritic cell vaccination confers significant anti-tumor immunity in hepatocellular carcinoma cells , 2018, PloS one.

[105]  R. Vile,et al.  Infectious Optimism following the 10th International Oncolytic Virus Meeting , 2017 .

[106]  Stephen J. Schuster,et al.  Chimeric Antigen Receptor T Cells in Refractory B‐Cell Lymphomas , 2017, The New England journal of medicine.

[107]  A. Gadducci,et al.  Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research. , 2017, Anticancer research.

[108]  D. Karan Formulation of the bivalent prostate cancer vaccine with surgifoam elicits antigen-specific effector T cells in PSA-transgenic mice. , 2017, Vaccine.

[109]  M. Honda,et al.  The in vivo antitumor effects of type I-interferon against hepatocellular carcinoma: the suppression of tumor cell growth and angiogenesis , 2017, Scientific Reports.

[110]  A. Khaled,et al.  Cytokines in immunogenic cell death: Applications for cancer immunotherapy , 2017, Cytokine.

[111]  A. Iyer,et al.  PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome , 2017, Front. Pharmacol..

[112]  Hui Peng,et al.  An epithelial-to-mesenchymal transition-inducing potential of granulocyte macrophage colony-stimulating factor in colon cancer , 2017, Scientific Reports.

[113]  F. Marincola,et al.  Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. , 2017, European journal of cancer.

[114]  Y. Kodera,et al.  Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials , 2017, Front. Oncol..

[115]  Xingchun Gou,et al.  Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy , 2017, Front. Immunol..

[116]  Yuhua Wang,et al.  Exosomes from M1-Polarized Macrophages Potentiate the Cancer Vaccine by Creating a Pro-inflammatory Microenvironment in the Lymph Node. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[117]  K. Shen,et al.  Recent progress in GM-CSF-based cancer immunotherapy. , 2017, Immunotherapy.

[118]  W. Dougall,et al.  TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy , 2017, Immunological reviews.

[119]  J. Altomonte,et al.  Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a “Hammer” and “Anvil” , 2017, Biomedicines.

[120]  D. Lambrechts,et al.  Centrosome Amplification Is Sufficient to Promote Spontaneous Tumorigenesis in Mammals. , 2017, Developmental cell.

[121]  M. Kudo Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials , 2017, Oncology.

[122]  H. Heslop,et al.  Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[123]  Yousef Ahmed Fouad,et al.  Revisiting the hallmarks of cancer. , 2017, American journal of cancer research.

[124]  H. Sultan,et al.  Designing therapeutic cancer vaccines by mimicking viral infections , 2017, Cancer Immunology, Immunotherapy.

[125]  Connie Y. C. Ma,et al.  Tigit, CD226 and PD-L1/PD-1 Are Highly Expressed By Marrow-Infiltrating T Cells in Patients with Multiple Myeloma , 2016 .

[126]  H. Fukuhara,et al.  Oncolytic virus therapy: A new era of cancer treatment at dawn , 2016, Cancer science.

[127]  H. Kohrt,et al.  Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[128]  Ryan M. O’Connell,et al.  Genome-Wide CRISPR-Cas9 Screen Identifies MicroRNAs That Regulate Myeloid Leukemia Cell Growth , 2016, PloS one.

[129]  J. Banchereau,et al.  The Human Vaccines Project: A roadmap for cancer vaccine development , 2016, Science Translational Medicine.

[130]  M. Mita,et al.  Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity. , 2016, World journal of methodology.

[131]  Nicolai J. Birkbak,et al.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.

[132]  Yao Wang,et al.  Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report , 2016, Signal Transduction and Targeted Therapy.

[133]  Clarke Brian Blackadar,et al.  Historical review of the causes of cancer. , 2016, World journal of clinical oncology.

[134]  E. Buchbinder,et al.  CTLA-4 and PD-1 Pathways , 2016, American journal of clinical oncology.

[135]  J. Diallo,et al.  Oncolytic Viruses: Exploiting Cancer's Deal with the Devil. , 2015, Trends in cancer.

[136]  David L. Porter,et al.  Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia , 2015, Science Translational Medicine.

[137]  J. E. Brewer,et al.  NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma , 2015, Nature Medicine.

[138]  S. Ghafouri-Fard,et al.  MAGE-A3: an immunogenic target used in clinical practice. , 2015, Immunotherapy.

[139]  L. Zitvogel,et al.  Type I interferons in anticancer immunity , 2015, Nature Reviews Immunology.

[140]  Troy Guthrie,et al.  Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[141]  Joe-Marc Chauvin,et al.  TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients. , 2015, The Journal of clinical investigation.

[142]  Michel Sadelain,et al.  The journey from discoveries in fundamental immunology to cancer immunotherapy. , 2015, Cancer cell.

[143]  S. Rosenberg,et al.  Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.

[144]  J. Hackney,et al.  The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. , 2014, Cancer cell.

[145]  Yang Liu,et al.  Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. , 2014, Clinical immunology.

[146]  P. Chong,et al.  Depletion of tumor-associated macrophages enhances the anti-tumor immunity induced by a Toll-like receptor agonist-conjugated peptide , 2014, Human vaccines & immunotherapeutics.

[147]  C. Breitbach,et al.  Going viral with cancer immunotherapy , 2014, Nature Reviews Cancer.

[148]  S. Rosenberg IL-2: The First Effective Immunotherapy for Human Cancer , 2014, The Journal of Immunology.

[149]  N. Agarwal,et al.  Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.

[150]  S. Rabkin,et al.  Oncolytic Viruses and Their Application to Cancer Immunotherapy , 2014, Cancer Immunology Research.

[151]  I. Wauters,et al.  Melanoma-associated antigen-A3 vaccination in the treatment of non-small-cell lung cancer , 2014, Expert opinion on biological therapy.

[152]  Jennifer Couzin-Frankel,et al.  Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.

[153]  D. Lyles,et al.  Signaling Pathways in Murine Dendritic Cells That Regulate the Response to Vesicular Stomatitis Virus Vectors That Express Flagellin , 2013, Journal of Virology.

[154]  E. Keller,et al.  Mechanisms of Metastatic Tumor Dormancy , 2013, Journal of clinical medicine.

[155]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[156]  J. Banchereau,et al.  Dendritic-cell-based therapeutic cancer vaccines. , 2013, Immunity.

[157]  R. Bei,et al.  Carcinoembryonic antigen (CEA)-based cancer vaccines: recent patents and antitumor effects from experimental models to clinical trials. , 2012, Recent patents on anti-cancer drug discovery.

[158]  S. Russell,et al.  ONCOLYTIC VIROTHERAPY , 2012, Nature Biotechnology.

[159]  C. Yun,et al.  Strengthening of antitumor immune memory and prevention of thymic atrophy mediated by adenovirus expressing IL-12 and GM-CSF , 2011, Gene Therapy.

[160]  D. Jocham,et al.  Prostate Cancer Vaccines , 2012, BioDrugs.

[161]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[162]  L. Lerescu,et al.  Influence of Tumor Cell Culture Supernatants on Macrophage Functional Polarization: In Vitro Models of Macrophage-tumor Environment Interaction , 2011 .

[163]  Aaron Fenster,et al.  Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans , 2011, Nature.

[164]  P. Darcy,et al.  Autoimmunity associated with immunotherapy of cancer. , 2011, Blood.

[165]  L. Harrington,et al.  Cytokines and the inception of CD8 T cell responses. , 2011, Trends in immunology.

[166]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[167]  H. Young,et al.  An Overview of Cytokines and Cytokine Antagonists as Therapeutic Agents , 2009, Annals of the New York Academy of Sciences.

[168]  N. Stanietsky,et al.  The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity , 2009, Proceedings of the National Academy of Sciences.

[169]  D. Green,et al.  Immunogenic and tolerogenic cell death , 2009, Nature Reviews Immunology.

[170]  E. Kremmer,et al.  CD96 Interaction with CD155 via Its First Ig-like Domain Is Modulated by Alternative Splicing or Mutations in Distal Ig-like Domains* , 2009, Journal of Biological Chemistry.

[171]  F. Hirsch,et al.  MAGE A3 antigen-specific cancer immunotherapeutic. , 2009, Immunotherapy.

[172]  L. Emens Cancer vaccines: on the threshold of success , 2008, Expert opinion on emerging drugs.

[173]  S. Rosenberg,et al.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy , 2008, Nature Reviews Cancer.

[174]  A. Simpson,et al.  MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. , 2007, Cancer research.

[175]  H. Fang,et al.  Clinical trials with oncolytic adenovirus in China. , 2007, Current cancer drug targets.

[176]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[177]  M. Lai,et al.  Development of a conditionally replicating pseudorabies virus for HER-2/neu-overexpressing bladder cancer therapy. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[178]  Gang Wang,et al.  A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer , 2006, Clinical Cancer Research.

[179]  R. Madan,et al.  PSA-based vaccines for the treatment of prostate cancer , 2006, Expert review of vaccines.

[180]  G. Zhu,et al.  Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. , 2005, Cancer research.

[181]  Ira Mellman,et al.  Cell biology of antigen processing in vitro and in vivo. , 2005, Annual review of immunology.

[182]  Circe Mesa,et al.  Challenges facing adjuvants for cancer immunotherapy , 2004, Immunology and cell biology.

[183]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[184]  G. Schwarzer,et al.  Impact of granulocyte colony‐stimulating factor (CSF) and granulocyte–macrophage CSF in patients with malignant lymphoma: a systematic review , 2003, British journal of haematology.

[185]  H. Pehamberger,et al.  A genetically engineered influenza A virus with ras-dependent oncolytic properties. , 2001, Cancer research.

[186]  B. Foster,et al.  Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. , 2000, Cancer research.

[187]  M. Tagawa Cytokine therapy for cancer. , 2000, Current pharmaceutical design.

[188]  K. Aozasa,et al.  Cancer Immunotherapy Targeting Wilms’ Tumor Gene WT1 Product1 , 2000, The Journal of Immunology.

[189]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[190]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[191]  P. Romero,et al.  Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes , 1994, The Journal of experimental medicine.

[192]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[193]  D. Scheinberg,et al.  Monoclonal antibody therapy of cancer. , 1990, Cancer chemotherapy and biological response modifiers.

[194]  Z. Eshhar,et al.  Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[195]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[196]  A. Chang,et al.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.

[197]  S. Rosenberg,et al.  Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2 , 1985, The Journal of experimental medicine.

[198]  L. Old,et al.  T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[199]  P. Marrack,et al.  The major histocompatibility complex-restricted antigen receptor on T cells. I. Isolation with a monoclonal antibody , 1983, The Journal of experimental medicine.

[200]  T. Taniguchi,et al.  Structure and expression of a cloned cDNA for human interleukin-2 , 1983, Nature.

[201]  Richard A. Miller,et al.  RESPONSE OF CUTANEOUS T CELL LYMPHOMA TO THERAPY WITH HYBRIDOMA MONOCLONAL ANTIBODY , 1981, The Lancet.

[202]  S. Rosenberg,et al.  In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. , 1980, Journal of immunology.

[203]  F. Stevenson,et al.  Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: a therapeutic target. , 1977, Federation proceedings.

[204]  R. Gallo,et al.  Selective in vitro growth of T lymphocytes from normal human bone marrows. , 1976, Science.

[205]  R L Kassel,et al.  An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[206]  I. Hellstrom,et al.  Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen--antibody complexes. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[207]  E. Haese Treatment of Inoperable Cancer , 1902, Medizinische Klinik.

[208]  James B. Murphy FACTORS OF RESISTANCE TO HETEROPLASTIC TISSUE-GRAFTING : STUDIES IN TISSUE SPECIFICITY. III. , 1914 .